MedTrace Logo

ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)

NCT00160680 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2023-08-31

Study results available
· View outcomes & findings →

Summary

Comparison of clinical efficacy and safety of levocetirizine in PER continuous versus on demand, measured by evolution of individual symptom scores during 6 months.

Conditions

  • Rhinitis, Allergic, Perennial

Interventions

DRUG

Levocetirizine

* Pharmaceutical form: Tablet * Concentration: 5 mg * Route of administration: Oral use

Sponsors & Collaborators

  • UCB S.A. - Pharma Sector

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-01
Primary Completion
2006-06-01
Completion
2006-06-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00160680 on ClinicalTrials.gov